BioCentury
ARTICLE | Clinical News

Mylan expecting another delay for generic Advair

June 15, 2018 7:58 PM UTC

Mylan N.V. (NASDAQ:MYL) said it expects to receive a second complete response letter from FDA for an ANDA of a generic version of Advair salmeterol/fluticasone from GlaxoSmithKline plc (NYSE:GSK; LSE:GSK).

Any delay would be a reprieve for GSK, which reported worldwide Advair sales of £3.1 billion ($4.2 billion), including U.S. sales of £1.6B ($2.2 billion), last year. ...

BCIQ Company Profiles

GSK plc

Mylan N.V.